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Abstract
Obesity and type 2 diabetes increase the risk of and reduce survival in breast 
cancer (BC) patients. Metformin is the only anti-diabetic drug that alters this 
risk, with a reduction in BC incidence and improved outcomes. Metformin has 
AMP-kinase (AMPK) dependent and independent mechanisms of action, most 
notably affecting the liver and skeletal muscle. We and others have shown that 
metformin also downregulates protein and lipid synthesis; deactivates various 
receptor tyrosine kinases; alters cell cycle transcription/translation; modulates 
mitochondrial respiration and miRNA activation; targets key metabolic molecules; 
induces stem cell death and may induce apoptosis or autophagy in BC cells. Many of 
these anti-cancer effects are molecular subtype-specific. Metformin is most potent 
against triple negative (basal), followed by luminal BCs. The efficacy of metformin, 
as well as dose needed for the activity, is also modulated by the extracellular glucose 
concentration, cellular expression of the glucose transporter protein 1 (GLUT1), 
and the organic cation transporter protein 1 (OCT1, which transports metformin 
into cells). This chapter summarizes the diverse clinical and preclinical data related 
to the anti-cancer effects of metformin, focused against breast cancer.
Keywords: metformin, breast cancer, TGF-β, STAT3, and PI3K/AKT/mTOR, FASN, 
MiR-193b, cancer stem cells, EGFR, cholesterol, glucose
1. Introduction
Metabolic dysregulation of carbohydrate and lipid metabolism is frequent in 
cancer cells, facilitating growth and survival through adaptive mechanisms. Otto 
Warburg was the first to recognize that cancer cells favor glycolysis as compared 
to oxidative phosphorylation for the generation of energy (ATP) [1]. While the 
former is less efficient in terms of energy production per molecule of glucose, it 
also generates precursor molecules (amino acids, fatty acids, etc.) for replication 
and facilitates survival under oxidative stress [2]. This is in contrast to normal cells, 
which typically use oxidative metabolism to derive more energy (ATP) per molecule 
of glucose [3, 4]. Nearly a century later, we now recognize that cancer cells may 
utilize either aerobic or anaerobic respiration. The majority of cancer cells also have 
alterations of mitochondrial respiration, further providing a selective advantage to 
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facilitate cancer growth and survival [5]. More specifically, it may increase intracel-
lular reactive oxygen species by disruption of the mitochondrial electron transport 
chain to reduce the mitochondrial membrane potential in BC or act directly to 
inhibit the mitochondrial respiratory-chain complex 1 (MRCC1) [6–8].
Chronic energy excess and physical inactivity lead to systemic alterations of 
carbohydrate and fatty acid metabolism characterized by systemic hypergly-
cemia, hyperinsulinemia with insulin resistance followed by hypoinsulinemia, 
an increase in inflammatory cytokines and adipokines, alterations of steroid 
and growth hormones, and downregulation of immune surveillance and tissue 
oxygenation [3, 9, 10]. These changes are frequent but variable in patients with 
obesity and type 2 diabetes and can be modified by drugs, exercise, body weight, 
socioeconomic factors, access to healthcare, genetic risk, and other factors. 
Patients with these disorders are at an increased risk of cardiovascular disease, 
cancer, and other diseases associated with significant morbidity and mortality.  
In the U.S., there are ~13.8 million type 2 diabetics, 5 million undiagnosed diabet-
ics, and 41 million persons with prediabetes/metabolic syndrome [11–13]. Obesity 
is a frequent comorbidity, often proceeding diabetes by years or decades.
Energy-sensing systems are integral to maintaining homeostasis in normal and 
transformed cells. Energy deprivation is frequent in cancer cells due to an inad-
equate vascular supply to meet the needs of increased cell replication.  
In energy-stressed cells, AMPK is allosterically modified by binding to AMP and 
ADP, rendering them targetable by AMPK kinases. AMPK activation induces 
signaling, upregulates energy production, and inhibits energy programming for 
cell growth and motility. In cancerous cells, this shift often fails to occur even with 
stress. As a result, cancer cells typically prioritize replication and motility to favor 
cancer growth and metastasis. Drugs that activate AMPK, most notably metformin, 
reengage the AMPK failsafe to inhibit proliferation and motility. Thus, metformin 
provides a unique and generally less-toxic approach to combat the emergence 
or growth of cancers through inhibition of cell replication. This is particularly 
important for patients with obesity and type 2 diabetes, who lack homeostasis and 
experience wide swings in systemic glucose, insulin, and other energy precursors 
and growth factors that contribute to systemic energy stress.
2. Metabolic dysregulation, breast cancer, and metformin
Abundant epidemiologic and clinical data have shown that obesity and type 2 
diabetes increase the risk and severity of cardiovascular disease and human cancer. 
Each of these chronic metabolic disorders as a single variable significantly increases 
the risk of breast cancer (BC) [10, 14]. In combination, the risk is increased by 
20–50%, depending on the severity of disease and other variables. It is highest in 
women with abdominal (central) obesity in the postmenopausal setting, in women 
of all ethnic backgrounds [15–17]. Obesity also promotes BC in premenopausal 
women of color, especially African Americans and Latinos [18–23]. In patients with 
obesity and diabetes, BC also presents at a higher disease stage and is more resistant 
to treatment, resulting in a shorter disease-free interval and a significantly higher 
mortality rate [24, 25].
Steroid receptor-positive BC (luminal A) and basal (triple negative) BC cells are 
the most responsive to extracellular glucose at or above 7 mM of glucose to promote 
cell replication, tumor growth, and motility. In contrast, steroid receptor-positive 
BC cells that also express high HER2 (luminal B) and steroid receptor-negative, 
HER2 positive (the HER2 subtype) are less responsive to hyperglycemia, even at 
levels associated with untreated type 2 diabetes (10 mM glucose or higher) [26]. 
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Glucose directly promotes signaling in epithelial cells or can act indirectly by 
interacting with molecular signaling proteins, such as the insulin-like growth factor 
(IGF-1), sex hormones, and adipokines [3, 27, 28]. Insulin and insulin-like growth 
factors are frequently increased in newly diagnosed BC patients [28–31]. These 
potent growth factors promote BC growth and are associated with a worse progno-
sis, both in overweight and ‘normal’ weight women [24, 29, 32–34]. Epidemiological 
and clinical data show that obesity and type 2 diabetes are particularly associated 
with luminal A (estrogen and progesterone responsive) as well as triple negative 
BCs [19, 21, 27, 35, 36].
Metformin (N′, N′-dimethylbiguanide) is the most frequently used drug to treat 
patients with metabolic syndrome (prediabetes) and type 2 diabetes worldwide. 
It has been used successfully for over six decades and has a very favorable benefit-
risk profile [37]. Metformin is stable at room temperature with a long shelf life, is 
inexpensive and orally administered, and has low rates of significant toxicity or 
drug-drug interaction. Metformin is best known for its effects on liver and skeletal 
muscle cells, where it downregulates insulin resistance, lowers serum insulin, 
stimulates insulin receptor tyrosine kinase activity, inhibits hepatic glucose output 
(thus lowering A1C), increases glucose uptake by skeletal muscle cells, and can alter 
fatty acid metabolism.
Epidemiologic data show a significant lowering of cancer risk in patients with 
metabolic dysregulation (obesity, diabetes, or metabolic syndrome) who take 
metformin [29, 34, 38, 39]. Metformin use by BC patients has also been associated 
with improved treatment response and survival. In one meta-analytic study of BC 
patients with diabetes, metformin use was associated with a 65% improvement in 
BC-specific survival as compared to nonusers [40]. The anticancer properties of 
metformin are in contrast to other antidiabetic agents, including sulfonylureas and 
insulin, which promote cancer growth [9].
It is also taken for its ‘antiaging’ properties in individuals without obesity or 
metabolic dysregulation, particularly outside of the US [10, 41, 42].
Numerous clinical trials are currently underway in BC patients to evaluate the 
benefit of metformin combined with or following the administration of other 
therapeutic agents [29, 32, 33, 43–46]. Studies designed to test the benefit of 
metformin in patients in only specific molecular subtypes of BC have not been per-
formed, although some have looked at molecular cohort interactions as a secondary 
goal [30, 47–51]. There are limited data on the use of metformin in metabolically 
‘normal’ BC patients. However, our preclinical data suggest that metformin is most 
active in all molecular subtypes with physiological levels of extracellular glucose 
[26]. This evidence provides a rationale for testing metformin in otherwise healthy 
BC patients.
3. AMPK-dependent mechanisms of metformin action in BC
Cellular uptake of metformin requires expression and functionality of the organic 
cation transporter 1 (OCT1) protein, which in some individuals or BCs may be 
altered (more or less effective in transporting metformin into the cell) by polymor-
phism or genetic error [52]. Polymorphisms have also been associated with a decrease 
in metformin efficacy in diabetic patients [53–55]. In BC cells, we have demonstrated 
that OCT1 expression is associated with the anticancer activity in vivo [44]. Once 
inside the cell, metformin may directly interact with the metabolic sensor AMPK to 
induce activation, restoring homeostasis and blocking cellular replication and motil-
ity under low energy (stress) conditions. The AMPK ‘switch’ is also influenced by the 
intracellular AMP:ATP ratio, which in turn is influenced by fatty acid oxidation and 
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glucose metabolism. Thus, metformin can indirectly affect AMPK, through reduction 
of gluconeogenesis and thus changing of the AMP:ATP ratio. These mechanisms are 
represented in Figure 1. These processes are modulated by P53 status. It is mutated 
in many BCs, particularly tumors that are high grade, late-stage or nonluminal in 
subtype. In BCs that are P53 competent, AMPK activation (from metformin or other 
triggers) upregulates P53 tumor suppressor activity as a downstream target. This 
induces activation of cell cycle checkpoint proteins, to inhibit cell proliferation [56]. 
In P53 incompetent cells, AMPK activation from metformin may be less effective 
through P53 mechanisms. Given the numerous other actions of metformin, as well 
as the molecular subtype specificity of the drug, we postulated that P53 status alone 
would not have a major impact on anticancer effects of metformin. We have dem-
onstrated that this is the case in preclinical studies of numerous BC cell lines [57]. In 
other cells, metformin may induce cell cycle arrest and death through activation of 
apoptotic pathways and downregulation of p53 [58, 59] or PARP cleavage, especially 
in triple negative BC [60, 61].
Activation of mTOR-dependent protein synthesis and cell growth (downstream 
of the PI3K/Akt signaling axis), along with AMPK, provides a robust signal-
ing platform for BC cell growth, proliferation, and chemotherapy resistance. In 
addition to activating AMPK, metformin inhibits mTOR and downstream signal-
ing components of this critical pathway. Mutation of the PI3K catalytic subunit 
(PIK3CA) occurs in 20-35% of BCs [62, 63]. Mutation or loss of the tumor suppres-
sor gene PTEN has also been demonstrated in 40% of BC [64, 65]. Metformin can 
also inhibit gluconeogenesis and mTOR signaling independent of AMPK and the 
tuberous sclerosis 2 (TSC2) gene in some experimental systems (in hepatic cells 
that lack AMPK or its kinase, LKB1). In this model system, metformin induces 
Figure 1. 
Metformin AMPK-dependent mechanism of action on breast cancer. Metformin activates AMPK directly 
through insulin-like growth factor (IGF-I) or insulin receptor, which in turn can activate PI3K/Akt/mTOR 
or RAS/Raf/MEK/ERK to increase cell growth, survival, angiogenesis, migration, and invasion. Metformin 
indirectly activates AMPK, which activates mTORC2, CREB, and gluconeogenesis. Lastly, glucose can enter BC 
cell through GLUT-1, and metformin can directly downregulate GLUT-1 receptor.
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downregulation of hepatic gluconeogenesis through non-AMPK–associated 
mechanisms [66, 67].
Signaling systems and thus metformin sensitivity by dose or mechanism vary 
by the molecular subtype of BC as well as unique genomic changes in each patient’s 
BC. For example, we have shown that metformin-induced partial S phase arrest 
increased P-AMPK and reduced P-EGFR, P-MAPK, P-Src, cyclin D1, and cyclin E, 
with the induction of PARP cleavage and apoptosis only in triple negative BCs [44]. 
In this tumor subtype, metformin specifically targets Stat3 and is not dependent on 
mTOR signaling [44]. In non-triple negative BCs (luminal and HER2), metformin 
induces partial cell cycle arrest at the G1 checkpoint, reduces cyclin D1 and E2F1 
expression, and inhibits AMPK, MAPK, Akt, and mTOR activity [44, 57, 68]. 
Metformin-associated AMPK activation may also inactivate the insulin receptor 
substrate 1 (IRS1), which in turn regulates IGF-IR and PI3K/Akt signaling pathways 
to block the progrowth effects of hyperinsulinemia and insulin-like growth factors 
typically associated with type 2 diabetes [66, 67, 69].
Metformin is unique in the breadth and complexity of AMPK-dependent direct 
and indirect targets that inhibit cancer. Several new mechanisms fall into the rap-
idly expanding field of immuno-oncology. Metformin-induced activation of AMPK 
activates the programmed death ligand-1 (PDL-1) at S195, reducing stability and 
membrane localization and thus increasing PDL-1 degradation [70]. Metformin 
also promotes cytotoxic T cell lymphocyte activity in tumor tissue and enhances 
tumor-associated immune surveillance [6, 70, 71]. Additionally, metformin upregu-
lates pro-inflammatory cytokines (tumor necrosis factor alpha (TNFα), interleu-
kin-6 (IL-6), IL-1β, the nuclear factor kappa-light-chain-enhancer of activated 
B-cells (NF-κB), the hypoxia-inducible factor 1-alpha (HIF-1α), and the vascular 
endothelial growth factor (VEGF), reviewed in [72, 73]).
AMPK-dependent mechanisms of action have been validated using clinical 
trial–derived BC samples as well as preclinical model systems, reviewed in detail 
elsewhere [43]. Some of these were especially important to spur the expansion 
of metformin use in BC patients. The timing, dose, and duration of metformin 
treatment in BC patients with or without other chemotherapy are actively under 
investigation. Neoadjuvant metformin, in particular, has shown benefit with 
a higher rate of complete pathological response, as compared to similar BC 
patients [74].
3.1  Metformin targets cell cycle proteins in AMPK-dependent manner 
in breast cancer
AMPK plays an integral role in the regulation of cell cycle and cell division. 
The ability of metformin to activate AMPK thus has a significant inhibitory effect 
on cell-cycle associated proteins. This mechanism is represented in Figure 2. 
Expression profiling of BC derived from metformin-treated patients as compared 
to controls has shown consistent downregulation of many gene encoding proteins 
involved in mitosis, including kinesins, tubulins, histones, Aurora, as well as 
Polo-like kinases and ribosomal proteins (critical for protein and macromolecular 
biosynthesis, respectively) [75]. Given the targeted effects of metformin, it is not 
surprising that its actions are synergistic with drugs like paclitaxel that induce 
defects in mitotic spindle assembly, chromosome segregation, and cell division. In 
combination, metformin and paclitaxel dramatically increase the number of cells 
arrested in G2-M and apoptosis, as compared to either agent alone [76]. Metformin 
may also induce GO/G1 arrest due to activation of AMPK, downregulation of cyclin 
D1, and enhanced binding of CDK2 by p27Kip1 and p21cip1 [60, 61], especially in 
non-triple negative cells. Some have shown that metformin sensitivity to GO/G1 
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arrest is linked to overexpression of p27Kip1 p21cip1 [60, 61]. We have demonstrated 
that metformin induces cycle arrest at the G1 checkpoint in luminal A, B and 
HER2 BC [75] associated with a reduction of cyclin D1 and E2F1 expression, with 
no changes in p27Kip1 or p21waf1. While these authors describe how metformin can 
increase CDK chemical inhibitors to control BC growth [57, 61], others have utilized 
cell cycle-dependent kinases (CDK) inhibitors with metformin and report that this 
combination should be used with caution [77].
In addition to downregulating cell replication under stress, metformin upregu-
lates the cellular DNA-damage response, resulting in a decline in the mutational 
burden for those cancer cells that survive. Mechanisms underlying this effect 
include selective activation of the ataxia telangiectasia mutated (ATM) gene as well 
as ATM targets, such as protein kinase CHK2 gene and attenuation of reactive oxy-
gen species ROS that result in DNA damage [78]. Algire et al. have postulated that 
downregulation of ROS production and thus somatic mutation are likely contribut-
ing mechanisms for the reduction in cancer risk associated with metformin use [8].
In summary, AMPK plays a central regulatory role in human cells, including BC 
where it regulates energy metabolism, cell growth and motility, response to insulin 
and growth factors, and estrogen production. Metformin induces AMPK activation 
in a robust manner, to affect numerous target pathways and intermediate molecules. 
The activity of AMPK and thus metformin can be modified by interacting factors 
including hormones, growth factors, and energy sensors. Selective targeting of 
AMPK-dependent pathways has shown less efficacy than metformin alone against 
BC [79], consistent with the findings that not all mechanisms of metformin action 
are AMPK dependent.
Figure 2. 
AMPK-dependent action on cell cycle and alternate mechanisms. Metformin activates AMPK directly 
through insulin-like growth factor (IGF-I) or insulin receptor, which in turn can activate PI3K/Akt/mTOR 
or RAS/Raf/MEK/ERK signaling pathway. Metformin can also inhibit downstream signaling intermediates 
to attenuate autophagy, mRNA translation, cell growth, ribosome biogenesis, protein synthesis, and cell cycle 
growth. Metformin can also activate AMPK, which blocks P53 and induces cell cycle arrest. Lastly, metformin 
can block complex I of mitochondrial biogenesis to increase intracellular O2, which can block HIF-1 and VEGF 
production.
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4. AMP-independent mechanisms of action on metformin
4.1 Metformin action on glucose and metabolism
Upregulation of bioavailable glucose, insulin, and other growth factors increase 
the risk and promote BC aggression [16, 23, 27, 80, 81]. In addition to shifts in host 
metabolism, glycolytic reprogramming occurs in breast epithelial cells during 
malignant transformation. This process is accentuated by systemic dysregulation of 
carbohydrate and lipid metabolism, as bioavailable sugars and fat typically increase 
in these patients. Glycolytic reprogramming includes dependence on aerobic res-
piration, providing less-efficient energy (ATP) production per molecule of glucose 
from and incomplete oxidative phosphorylation. Cancer cell reprogramming 
includes activation of numerous signaling intermediaries, including phosphatidyl-
inositide 3-kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin 
(mTOR), phosphatase and tensin homolog (PTEN), and AMPK [82–84]. Changes 
in other factors including c-MYC, hypoxia-inducible factor 1-alpha (HIF1α), 
epidermal growth factor receptor (EGFR), tumor protein 53 (P53), and the Met 
receptor may also facilitate cancer cell dependence on aerobic glycolysis [16, 85–87].
We have focused on the effects of extracellular glucose and other carbohydrates, 
combined with or without metformin using BC cell lines and animal models of obesity, 
metabolic syndrome, and mammary tumorigenesis, summarized in Figure 3 and 
detailed elsewhere [26, 47, 49, 52, 57, 68, 88–93]. Importantly, most in vitro studies of 
metformin use commercially purchased media containing ~17 mM glucose (incompat-
ible with human life, above concentrations achieved in diabetes). This is significantly 
higher than serum derived from normal persons (~5 mM), metabolic syndrome 
patients (~7 mM), or uncontrolled diabetes (~10 mM) [26]. We have shown that all 
molecular subtypes of BC cells grown with high glucose media require significantly 
more metformin to achieve the same anticancer efficacy (i.e., much higher EC50 
of metformin) [26]. Normalization of glucose concentration in the culture media 
significantly reduced the EC50 of metformin for all BC cell types to induce BC growth 
inhibition or death. This hyperglycemic override of metformin action by dose makes 
biologic sense, given the ability of glucose to enter cells and promote many of the same 
pathways we have shown that are critical to metformin action. Similar issues may arise 
in animal models, particularly if the animals are overfed or obese. In both mouse and 
rat model systems, we have achieved plasma metformin concentrations equivalent to 
the normal range in humans, by providing it in the drinking water. We have also shown 
that metformin accumulates in the cytoplasm, markedly higher than serum levels in 
mammary tumor cells with functional and sufficient OCT1 protein [26].
Luminal A and some subsets of triple negative BC cell lines show the greatest 
increase in proliferation when cultured in media with supraphysiologic glucose or 
insulin. In contrast, luminal B and HER2 BC cells were significantly less responsive 
to glucose or insulin, even at the highest concentrations examined. This responsivity 
pattern was similar to the cellular response to metformin by molecular BC subtype, 
with triple negative being the most responsive. From a molecular standpoint, triple 
negative BC cell responsivity to high glucose and metformin by dose was unique 
(efficacy at lower EC50s). Triple negative BC cells are especially dependent on 
glucose/glucosamine (metabolized through glycolysis) and lipids for energy and 
building block production, cell division, phenotypic aggression, and motility [94]. 
When grown with media containing supraphysiologic glucose, they upregulate 
specific genes, including EGFR, P-EGFR, IGF1R, P-IGF1R, IRS2, cyclin D1, and 
cyclin E expression, and inhibit AMPK/P-AMPK and p38 in a dose-dependent 
manner [26]. With the addition of metformin, there is a downregulation of these 
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genes and the upregulation of genes associated with cell killing and growth control 
[49, 94]. Our report showed that glucose promotes phenotypic aggression and 
reduces metformin efficacy by targeting key enzymes that are required for glucose 
metabolism in TNBC. Such enzymes include G6PD, Fructose-2-6-BP, PGK, PGM, 
ENO, PKM2, and LDH-A (shown in Figure 3 and reviewed in [49]). Further, 
we reported that metformin attenuated the expression of over 20 critical genes 
involved in glucose metabolism, glucose transporters, gluconeogenesis, and tricar-
boxylic acid cycle [49]. Metformin-associated gene expression changes also reduced 
phenotypic aggressiveness and stem-like progenitor cell pool [26, 49, 90, 92]. 
Metformin treatment also restricted cell proliferation with S phase arrest, motility 
(through downregulation of intermediate filament proteins), and increased apop-
tosis (through activation of both the intrinsic and extrinsic pathways) [26, 47, 57, 
88, 89, 92]. Metformin significantly inhibits carbohydrate induced pro-oncogenic 
metabolic and biologic characteristics of triple negative BC cells [26]. Altogether, 
metformin’s ability to target key glucose transporters, such a GLUT1, along with key 
genes involved in glucose and carbohydrate metabolism, highlights the role that this 
agent may play to control highly aggressive malignant BC cells via downregulation 
of the cellular metabolic machinery.
We have also shown that inhibition of lipid biosynthesis was requisite to the 
anticancer effects of metformin in triple negative BC cells. It downregulates both 
Figure 3. 
Metformin action on glucose and metabolism breast cancer. Metformin enters the BC cell through OCT 1 
transporter to attenuate inner membrane fluidity/permeability, the Krebs cycle (TCA), and complex I of the 
mitochondria. Metformin can also block downstream signaling intermediates involved in the PI3K/Akt/mTOR 
or RAS/Raf/MEK/ERK signaling pathways, which can control BC cell growth. Lastly, metformin blocks 
GLUT1 transporter and key enzymes that are involved in carbohydrate synthesis.
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fatty acid synthase (FASN) and the cholesterol biosynthesis pathway, as detailed 
below. Other studies have focused on interactions between obesity, weight gain, 
hormonal status, and BC, and more specifically if metformin could be used to 
disrupt this process. Using a rat model of mammary tumor development after 
exposure to a carcinogen, animals were overfed and then segregated into lean and 
obese. Both subsets were subjected to ovary removal, half were given metformin, 
and they were followed for the development and progression of mammary tumors 
[52, 93, 95]. Obese rats experienced marked changes in metabolism, akin to 
metabolic syndrome. Mammary tumors from these obese rats showed enhanced 
tumor growth and tumor-associated glucose uptake, 50% higher than nonobese 
rats in association with upregulation of the progesterone receptor. In contrast, the 
lean rats preferentially deposited excess nutrients in mammary (nontumor) and 
peripheral tissues. Metformin abrogated systemic metabolic dysregulation, reduced 
tumorigenesis, tumor progression, and tumor-associated PR expression in obese 
rats. Similar changes in body weight and obesity are frequent after female meno-
pause has been observed in BC of postmenopausal females with obesity, providing 
additional clues for the use and timing of metformin associated with BC risk and 
treatment for future study.
4.2 Metformin action on cholesterol, EGFR signaling, and lipid rafts
The mevalonate pathway, also known as the β-hydroxy β-methylglutaryl-CoA 
(HMG-CoA) reductase pathway, is critical for cancer cell survival. Inhibition of 
the pathway by statins or other agents has been shown to have anticancer effects 
[96, 97]. In contrast, elevated cholesterol has been strongly associated with BC 
risk, a worse BC-associated outcome and chemotherapeutic resistance. This 
reflects the pivotal role of lipids including cholesterol in cancer survival and 
growth, including upregulation of signaling through membrane-bound recep-
tors, facilitation of intracellular signaling pathways, and serving as an anchor for 
intracytoplasmic filaments to promote motility and invasion and as a precursor for 
cellular metabolism to generate energy and facilitate replication [98, 99]. We have 
shown that triple negative BC cells are especially dependent on the upregulation of 
lipid and cholesterol biosynthesis [100].
Statins are widely prescribed for patients with high cholesterol or lipid abnor-
malities, most often to reduce the risk of cardiovascular disease. Statins also benefit 
women to reduce the risk and disease progression of BC. Two population-based 
studies from Northern Europe are particularly compelling. A Finnish study involv-
ing over 30,000 women showed that statin use, pre- or post-BC diagnosis, reduced 
BC-specific mortality by about 50% [101]. A large Danish study showed a benefit 
for BC patients as well, with significantly lower recurrence rates in statin users 
as compared to nonusers. They also reported that lipophilic statins (rather than 
hydrophilic satins) had the most anti-BC activity [102]. A recent study from MD 
Anderson Cancer Center suggests that statin use is particularly beneficial for BC 
patients with triple negative tumors, especially in patients with higher stage disease 
[95]. Their data are consistent with our preclinical data, showing significant 
upregulation of lipid metabolism-associated gene triple negative BC as compared 
to other molecular subtypes. See for further discussion elsewhere [103]. A major 
issue with statin use is toxicity, which reportedly occurs in up to half of patients. 
Some statin drugs are also expensive and thus may be unaffordable by many 
patients.
Metformin, in contrast, is relatively nontoxic and inexpensive. We have dem-
onstrated that metformin has potent effects in lipid and cholesterol biosynthesis 
in BC cells. More specifically, it inhibits transcriptional activation of HMGCo-A 
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(the enzyme targeted by statins), as well as over 20 other genes in the cholesterol 
biosynthesis pathway. We have also shown that it induces translational activation 
of downstream signaling, including the genes ACAA2, HMGCS1, HMGCR, MVK, 
MVD, LSS, and DHCR24 (Figure 4). Through broad inhibition of cholesterol 
biosynthesis in triple negative BC, metformin induces a significant reduction of 
membrane-associated and intracellular cholesterol and reduces GM1 lipid rafts 
through decreased synthesis and destabilization (disassociation). GM1 lipid raft 
stability has a profound effect on some receptors that rely on GM1 lipid rafts (like 
EGFR) for stability, ligand binding, and thus activation, resulting in downstream 
signaling. We have shown that metformin inhibits cholesterol biosynthesis and 
raft production, reducing membranous EGFR and its activation associated with 
downstream signaling in TNBC [91]. We have also shown that in combination, 
metformin and the statin-mimetic MβCD were synergistic in attenuating choles-
terol biosynthesis and cell proliferation [91]. Others have validated our observation 
that metformin downregulates genes involved in cholesterol biosynthesis, reporting 
downregulation of HMGCR, LDLR, and SREBP1 [104]. A particularly exciting 
corollary of these findings is the potential of metformin to synergize with receptor 
tyrosine kinase inhibitors (RTKIs) against BC. This is an underexplored area of 
breast oncology research with tremendous translational potential, given the grow-
ing use of RTKIs against BC.
Figure 4. 
Metformin action on cholesterol synthesis and lipid rafts. Metformin blocks epidermal growth factor receptor 
(EGFR), human epidermal growth factor receptors 2/3 (HER2/HER3), which in turn can block key enzymes 
involved in cholesterol synthesis pathway. Metformin and statins both can inhibit rate limiting step HMG-CoA 
Reductase, HMGCR. Metformin can also decrease cellular membrane rigidity, increase fluidity, and decrease 
cholesterol content to allow for the internalization of EGFR, HER2, or HER3 receptors. Internalization of these 
receptors is through GM1 lipid rafts, which are degraded and allow for BC cell death.
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4.3 Metformin action on miRNA and FASN signaling
MiRNAs are endogenous, short (21-25) nucleotide sequences that control gene 
expression during post-transcriptional translation. It has previously been reported 
that more than half of human genes are regulated by miRNAs [105]. A growing 
body of evidence has highlighted the role of miRNAs as master regulators of meta-
bolic processes, such as lipid and cholesterol synthesis [92, 105, 106]. Perturbations 
of these processes are important for tumor development. Modulation of these 
regulators using synthetic antagomirs to block the activity of specific miRNAs is 
an important new area of breast research. Metformin exerts some of its anticancer 
activity through modulation of miRNAs that target genes in metabolic and other 
pathways (Figure 5) [92, 107, 108]. miRNAs have been reported to be potential 
biomarkers for BC (i.e., miR-9, miR-10b, and miR-17-5p), whereas others reportedly 
have prognostic (i.e., miR-148a and miR-335) or predictive relevance (i.e., miR-26a, 
miR-30c, miR-187, and miR-339-5p) [109].
We have shown that metformin increases several members of the miR-193 
family. It upregulates miR-193b, which in turn targets and downregulates the FASN 
3’UTR. FASN is an important component of de novo fatty acid synthesis. Using an 
miR-193b mimetic, we induced a drastic reduction in fatty acid synthase (FASN) 
protein expression as well as increased growth inhibition and apoptosis of TNBC 
[92]. A separate expression profiling study of metformin-treated TNBC cells has 
shown similar results [106]. These data show that inhibition of FASN and fatty acid 
biosynthesis contributes to the potency of metformin against BC cells.
Figure 5. 
Metformin action on lipid synthesis and miRNAs metformin blocks EGFR, HER2, and HER3, which in turn 
can block key enzymes involved in cholesterol synthesis pathway as described in Figure 4. Metformin can also 
block acetyl-CoA carboxylase (ACC), which in turn can decrease fatty acid synthase (FASN). Metformin 
can also increase a myriad of miRNAS (shown in green). One of these miRNAs (miR-193b) can target FASN, 




4.4 Metformin action on PI3K/Akt/mTOR signaling in breast cancer
The PI3K/Akt/mTOR pathway plays a central role in regulating protein syn-
thesis, cell proliferation, tumorigenesis, angiogenesis, tumor growth, and metas-
tasis [63]. While AMPK-dependent phosphorylation is frequently described in 
metformin-mediated inhibition of the PI3K/Akt/mTOR signaling pathway, AMPK 
activation is not mandatory for these effects; see schematic in Figure 6 [57]. We 
have shown that metformin inhibits Akt and mTOR and inhibits cellular prolifera-
tion and colony formation and causes a partial G1 cell cycle arrest in all ER-positive, 
HER2 normal or abnormal BC cell lines examined [57]. Metformin-mediated 
inhibition of the PI3K/Akt/mTOR signaling pathway has also been shown to induce 
inhibition of cell replication, S phase arrest, and apoptosis, with a reduction in E2F1 
and cyclin D1 expression in triple negative BC cell lines [57].
4.5 Metformin action in STAT3 signaling
TNBC shows high activation of the signal transducer and activator of transcrip-
tion 3 (STAT3) signaling pathway, which in turn promotes cell growth, invasion, 
migration, metastasis, angiogenesis, immune evasion, and drug resistance and 
inhibits apoptosis [88]. We have shown that metformin specifically targets STAT3 
signaling to reduce P-STAT3 at both Ser727 and Tyr705 phosphorylation sites but 
not STAT3 expression in TNBC, schematically represented in Figure 6. In com-
bination with a Stat3 inhibitor, metformin significantly downregulated STAT3 
Figure 6. 
Metformin action in breast cancer. Metformin can block receptor tyrosine kinase (RTK), such as EGFR, HER2, 
and HER3. Metformin further blocks downstream signaling intermediates involved in PI3K/Akt/mTOR or 
RAS/Raf/MEK/ERK signaling pathway, such as AKT, mTOR, MEK, or ERK, which can decrease cell growth, 
angiogenesis, and migration/invasion. Further, metformin can further block cytokine and growth factor 
receptors such as the TGF-RII. Metformin can block IL-6/STAT3 pathway and TGF-signaling pathway, which 
in turn can decrease cell growth, angiogenesis, migration/invasion, inflammation, and EMT.
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expression and was synergistic in reducing cell growth and the induction of apop-
tosis in TNBC [88]. Given that TNBC also shows an upregulation/activation of the 
PI3K/Akt/mTOR signaling pathways, we then combined metformin with an mTOR 
inhibitor rapamycin, to determine if it would reduce metformin efficacy. Significant 
interactions with metformin were not observed; thus, mechanisms underlying its 
effects are not dependent on mTOR.
The JAK/STAT pathway is upregulated by obesity-associated mechanisms that 
promote BC growth. Others have demonstrated that metformin attenuates Janus 
kinase (JAK)/STAT3 signaling at Ser515 and Ser518 within the Src homology 2 
domain of JAK1 [110]. Metformin has also been shown to preferentially inhibit 
nuclear translocation of NK-𝜅B and phosphorylation of STAT3 in cancer stem cells 
(CSCs) as compared to non-CSCs [111]. Given the procarcinogenic and prometa-
static role that JAK/STAT pathways play in TNBC, the development of therapeutic 
strategies to attenuate these pathways using metformin may provide benefit with 
limited toxicity.
4.6 Metformin and TGF-β signaling in TNBC
A subset of TNBC subclassified as mesenchymal-stem like/claudin-low (MSL/
CL) characteristically shows high expression and activation of TGF-β signaling, 
phenotypic aggression, and a worse outcome. In addition to TGF-β receptor 2 
expression, BC in this group shows upregulation of Smad2, Smad3, ID1, and ID3 
[90]. They are especially responsive to TGF-β ligand 1 (TGF-β1), resulting in cell 
proliferation, migration, and invasion. MSL/CL cell lines also demonstrate down-
regulation of several growth factor receptors in response to metformin, includ-
ing fibroblast growth factor receptors (FGFR2 and FGFR3), hormone receptors 
(AR, ESR1, and PGR), and claudin integral membrane proteins of tight junctions 
(CLDN3, CLDN4, and CLDN7) in the MSL/CL BC subtypes [90]. Metformin 
directly attenuated TGF-β signaling pathway by downregulating activation of 
Smad2/Smad3, ID1, and ID3 (Figure 6). In combination with TGF-β inhibitors 
(TβRI-KIs; LY2197s299 or SB431542), metformin synergistically enhanced cell 
death in MSL/CL BC cells [90]. Overall, these data suggest that targeting TGF-β 
signaling using metformin with or without a TGF-β inhibitor may provide benefit 
for patients with MSL/CL BCs.
The process of epithelial-mesenchymal transition (EMT) is also common in 
TNBC and has been associated with biologic aggression and stem-like properties. 
Metformin reportedly inhibits EMT in a metastatic canine model of mammary 
cancer [112]. Others have shown that metformin reduces EMT through block-
ade of transcription factors like ZEB1, TWIST1, and SNAIL (Slug) [113–115]. 
Given that TGF-β pathway activation and EMT promote breast cancer stem cells 
(BCSC), therapeutic resistance, dormancy, and a poor outcome [113], and that 
metformin has been shown to block these in TNBC, inhibitors against TGF-β-
induced EMT combined with metformin may provide benefit in some TNBC 
patients.
4.7  Metformin action on breast cancer and angiogenesis, and the 
microenvironment
Clinical studies have demonstrated that diabetic patients treated with met-
formin are less likely to develop cardiovascular disease, independent of glycemic 
control. It is unclear whether this outcome reflects downregulation of hyperglyce-
mia and systemic inflammatory triggers or vascular damage, or whether metformin 
has a direct effect on endothelial cells, vascular resistance, elasticity, and damage 
Metformin
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[12, 80, 116]. In the context of breast cancer, it has long been demonstrated that 
high-stage and grade cancers with a worse prognosis have the capacity to upregu-
late peri- and intratumoral neo-angiogenesis [117]. The induction of new vessels 
provides metabolic and oxygen delivery advantages to the cancer cells, facilitating 
survival and growth. Neo-angiogenesis is also associated with an increased capacity 
of the BC to metastasize, particularly to distant sites including the visceral organs 
and brain. We have demonstrated a reduction in vascular density and growth, in 
association with metformin treatment in preclinical models. Others have shown 
that metformin is associated with reduced tumor angiogenesis in many different 
cancer cell types. Metformin and alternate biguanides, such as phenformin, down-
regulate VEGF-dependent activation of ERK1, inhibiting neo-angiogenesis and 
reducing microvessel density (MVD) [118]. Wang et al. have shown that metformin 
also downregulates the expression of two other genes, platelet-derived growth 
factor B (PDGF-B) and fibroblast growth factor (FGF-2), to reduce angiogenesis 
[119]. Downregulation of PDGF-B also restricts BC cell proliferation, survival, and 
migration, [117]. Metformin’s effect on the microenvironment and angiogenesis 
has also been shown to enhance chemo-sensitivity, via a reduction in MVD leak-
age and cancer cell hypoxia in vivo [117]. Thus, metformin’s effects go beyond the 
cancer cell itself and include the peri- and intratumoral microenvironment and 
neovasculature.
Figure 7. 
Metformin action on breast cancer stem cells. Metformin can block a myriad of signaling pathways involved in 
BCSCs, including WNT, transforming growth factor (TGF), NOTCH, hypoxia inducible factor (HIF), and 
STAT3 signaling pathways. These pathways are thought to enrich for BCSC through the enrichment of CD44 
positive receptor and aldehyde dehydrogenase (ALDH+) and decrease in CD24 expression. Metformin can be 
given as a monotherapy or combinatorial therapy with alternate chemotherapeutic agents, which in turn can 
induce BCSC death with an increase in apoptosis, cell cycle arrest, and DNA damage. Overall, reduction in 
BCSCs can result in reduction of tumor growth and prevention in therapy-mediated relapse.
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4.8 Metformin action on breast cancer stem cells
Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are the 
progenitor cells that give rise to BC as well as heterogeneity within transformed 
populations. CSCs are maintained as a subpopulation within the neoplasm that 
perpetuates clonal expansion and may facilitate dormancy, metastasis, chemo-
resistance, and relapse. Among the molecular BC subtypes, TNBC shows the 
highest enrichment of CSCs, identified by expression patterns with flow cytometry 
as CD44+, CD24−/low CSC [120]. BC CSCs are particularly sensitive to metformin, 
which induces rapid cell death facilitated through a number of pathways involved 
in cell differentiation, renewal, metastasis, and metabolism (Figure 7). It directly 
targets key CSC gene signatures such as Notch 1, NFκB, Sox2, KLF-4, Oct4, Lin28, 
MMP-9, and MMP-2 [121]. Metformin attenuates CSCs in resistant BC, through 
repression of let-7 miRNA [121]. Its ability to attenuate key metabolic genes, such as 
FASN via upregulation of miR-193b, also contributes to its anti-CSC activity as stem 
cells are heavily dependent on aerobic glycolysis [92].
The capacity of metformin to induce CSC cell death has significant clinical 
relevance, given their role in therapeutic resistance, dormancy, and disease pro-
gression. Metformin reduces cancer recurrence through the preferential killing 
of differentiated rather than undifferentiated CSCs [122]. In combination with 
chemotherapy, metformin is especially active against BC CSCs [111]. In studies 
of trastuzumab-resistant BC cells as well as xenograft models, the combination 
of trastuzumab and metformin significantly reduced CD44+, CD24−/low CSC 
subpopulations and reduced tumor volume [111, 123, 124]. In combination with 
doxorubicin, paclitaxel, or carboplatin, metformin can also eradicate CSCs and 
reduce the effective dosage required of the highly toxic chemotherapeutic agents, 
minimizing patient risk [111, 123].
5.  Clinical evidence with metformin in breast cancer prevention 
and treatment
The pleiotropic oncostatic effects of metformin have been explored as an adju-
vant therapeutic option for the management of BC [43, 125, 126]. Epidemiological 
studies have demonstrated associations between metformin use in patients with 
type 2 diabetes and decreased cancer incidence and cancer-related mortality [10]. 
Several observational and randomized trials have evaluated a number of biomarker 
changes after metformin administration, increasing the footage of metformin as an 
off-label agent for BC. Over 11 ongoing and 13 completed clinical trials have tested 
the efficacy of metformin as a monotherapy or in combination with chemotherapy 
and/or radiotherapy for the management of BC (reviewed in [43, 127]). Goodwin 
et al. have shown that after six months of metformin treatment, a reduction in 
insulin by 22% had improved metabolic indices, such as insulin sensitivity, body 
weight, and cholesterol levels in nondiabetic patients with early-stage BC [29]. This 
information suggests that metformin is effective in the nondiabetic population. 
These data and other clinical trials further provide support in using metformin 
as an adjuvant agent as it is the only agent that does not promote BC but actually 
retards tumor growth. In addition, these clinical trials further support the need to 
screen for metabolic dysfunction and evaluate whether or not metformin should 
be integrated into the treatment for BC therapy. Further, BC patients receiving 
1500 mg/day of metformin showed a significant reduction in insulin levels and 
insulin resistance [44, 128]. The effect of metformin in response to neoadjuvant 
chemotherapy has been examined in diabetic BC patients. This study included 2529 
Metformin
16
women with BC and confirmed that metformin could achieve higher pathological 
complete response with neoadjuvant therapy relative to non-metformin users [129]. 
Dowling et al. have further examined neoadjuvant metformin in a prospective 
window of opportunity study [32]. Clinical and biological effects of metformin on 
nondiabetic BC patients were evaluated. These patients were treated with 500 mg 
of metformin three times daily for 2 weeks. Significant attenuated expression of the 
insulin receptor was observed in treated breast tumors and had high expression of 
OCT1 (organic cation transporter 1) [32]. The effect of metformin in nondiabetic 
BC patients was previously reviewed [43]. Systemic reviews and meta-analyses, 
highlighting a summary of studies involving metformin therapy in nondiabetic 
patients and diabetic patients, were reviewed in [43].
5.1 Metformin dose recommended for breast cancer patients
Pharmacokinetic profiling of mouse tumors provided preclinical analysis of 
appropriate human doses to provide efficient inhibition of tumor growth [130]. 
Based on this evidence, metformin-mediated activation of AMPK and antitumor 
function was dependent on cellular uptake of the drug, which is primarily con-
trolled by membrane transporters OCT1, OCT2, and OCT3 [131]. Based on the high 
expression of OCT transporters, 850 mg/day of metformin is required to inhibit 
tumor growth efficiently. If a tumor expresses low levels of OCT transporter, 
then 2250 mg/day is recommended [132]. Additionally, a dose of metformin of 
500–850 mg/day is typically recommended with standard chemotherapy (includ-
ing anthracyclines, platinum, taxanes, and capecitabine) for first- or second-line 
therapy (please see https://www.drugbank.ca/drugs/DB00331). The combination 
of metformin with a chemotherapeutic agent is recommended for a number of 
cycles until progression is unacceptable or toxicity develops.
5.2 Indications and contraindications for metformin use for breast cancer
Metformin is not approved for clinical use by the FDA and is still considered 
investigational for the treatment for BC. While metformin is well established as an 
inexpensive, well-tolerated, and effective for the treatment of diabetes, adjuvant 
use of metformin for BC remains to be defined. Current clinical trials have not 
outlined indications and contraindications for metformin use as adjuvant therapy 
for BC. Generally, metformin hydrochloride tablets are contraindicated in patients 
with (1) severe renal impairment (eGFR below 30 mL/min/1.73 m2), (2) hypersen-
sitivity to metformin, and (3) acute or chronic metabolic acidosis including diabetic 
ketoacidosis. Additionally, current clinical trials with metformin have been listed 
(https://clinicaltrials.gov/ct2/show/NCT01310231 and https://clinicaltrials.gov/ct2/
show/NCT01101438). The NCIC CTG MA.32 Phase III randomized clinical trial 
has completed enrollment of 3649 nondiabetic women receiving standard surgical, 
chemotherapeutic, hormonal, biologic, and radiation treatment for T1-3, N0-3, M0 
breast cancer. This trial has provided preliminary findings [33] and has not defined 
clear indications and/or contraindications for metformin use as adjuvant therapy 
for breast cancer.
6. Conclusions
A preponderance of clinical, epidemiological, and scientific evidence indicates that 
metabolic dysregulation of carbohydrate and lipid metabolism promote BC pathogen-
esis and a worse outcome, for women who have the disease [9, 10, 30, 40, 45, 129, 133]. 
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One of the therapeutic agents commonly used in patients with metabolic syndrome or 
type 2 diabetes, metformin, has demonstrated significant anti-BC activity. Metformin 
inhibits gluconeogenesis, reduces circulating levels of glucose, increases insulin 
sensitivity, and reduces hyperinsulinemia associated with insulin [134]. These factors 
have been associated with BC prognosis. Several mechanisms of metformin action 
involve AMPK-dependent and AMPK-independent signaling pathways, and these 
effects are remarkably broad and potent. Its ability to target metabolic dysregulation 
of carbohydrate and lipid metabolism as well as cancer stem cells appear to be equally 
important in its anticancer activity against BC [129, 133–137]. Furthermore, the 
effects of metformin are unique among molecular subsets of BC. A better understand-
ing of these mechanisms will facilitate targeted applications in patients with specific 
subtypes, fostering the goal of more personalized cancer care.
A number of clinical trials are underway to evaluate metformin in BC patients 
[30, 44–46, 50, 136]. Most have been designed to evaluate its efficacy, in combina-
tion with various chemo- or radiotherapy agents; see (https://clinicaltrials.gov/ct2/
results?term=+cancer+AND+metformin). Most ongoing or completed clinical trials 
have evaluated metformin’s effect on cellular proliferation or death, pathological 
response rate, progression-free or overall survival. Some have also sought to com-
pare its efficacy in patients with or without metabolic dysregulation, as a secondary 
aim. None have specifically been designed to evaluate interactions with CSCs, or in 
selected molecular subtypes, although correlative studies have provided some data 
in this regard. The ALTTO trial has shown that metformin improves outcomes for 
patients with diabetes and either HER2+ or hormone receptor positive BC [30]. The 
NCIC Clinical Trials Group (NCIC CTG) MA.32 has shown benefit from metfor-
min, as compared to placebo on outcomes in early stage BC [33]. It demonstrated 
efficacy with improvements in body weight, insulin, glucose, and leptin levels in BC 
patients examined, regardless of baseline BMI or fasting insulin levels [33].
In conclusion, metformin is a unique drug with a long track record of human 
use, which has demonstrated robust efficacy against type 2 diabetes and metabolic 
dysregulation. Epidemiologic data show independent and significant benefit in 
preventing cardiovascular disease and cancer in these patients. Metformin is an 
inexpensive oral agent that is currently available worldwide. It is generally well 
tolerated and has a low risk:benefit ratio. Epidemiological and clinical data have 
shown that metformin reduces BC incidence and mortality in women with meta-
bolic dysregulation, obesity, and type 2 diabetes. This subpopulation of woman 
is at significantly higher risk for BC, particularly in the postmenopausal setting. 
Preclinical and clinical evidence shows that metformin inhibits BC cell replication 
and tumor growth, decreases tumor aggression, reduces the stem cell pool, and 
slows motility/metastasis and can promote cell death through apoptosis, autophagy, 
or upregulation of immunity. Metformin has unique effects on molecular subsets of 
BC, with the aggressive triple negative BC showing the most sensitivity and lowest 
EC50 data. TNBC is particularly sensitive to metformin’s downregulation of fatty 
acid and cholesterol biosynthesis, glucose transport, and carbohydrate metabolism. 
This cancer subtype is typically the most aggressive and is less responsive to tradi-
tional chemotherapy; thus, metformin’s potency may provide significant benefit 
especially in these patients.
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